Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Sell

  • ROFR Required

  • Available in Depository:

  • NSDL

  • CDSL

  • Available for Investment:

  • Primary

  • Secondary

RATING

RECOMMENDATION

Sell

Business Type

Near Leader

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation

Snapshot
Key Ratio
Peers
Financials
Ownership
News
Events

RATING

RECOMMENDATION

Sell

Business Type

Near Leader

Discover and get a complete analysis on Sigachi Laboratories Limited - Management, Business Model, Financials, Growth, Valuations, Funding Rounds, News and get the latest updates on Sigachi Laboratories Upcoming IPO.

ISIN

INE368H01018

Face Value

₹10.00

Total Share

67,53,100

Total Income

₹385.70 L

Profit After Tax

₹275.41 L

EPS

₹4.08

P/E

14.22

P/B

1.68

Market Capitalisation

₹39.17 Cr

Enterprise Value

₹36.74 Cr

Book Value

₹34.54

Intrinsic Value

₹238.39

Earnings Yield

7.03 %

Sector

Health Care

Sub-sector

labs & Life Science Services

Category

Listed on Small Exchange

Cashflow - Operations

₹15.11 L

Sigachi Laboratories Growth

Compounded Sales Growth

  • 422.63%

    1 Year

  • 25.41%

    3 Year

  • 21.01%

    5 Year

Pro Only

Compounded Profit Growth

  • 289.79%

    1 Year

  • 35.33%

    3 Year

  • 28.34%

    5 Year

Pro Only

Return On Equity

  • 11.81%

    2021

  • 5.07%

    2019

  • 8.15%

    2017

Pro Only

About Sigachi Laboratories

  • Sigachi Laboratories Limited operates as a pharmaceutical company. The company focuses on the business of manufacturing bulk drugs and drug intermediates and also carries on investments in shares and securities. In FY21, the company generated most of its revenue from investments. 
  • Apart from manufacturing of drugs, company is also involved in investing, and mostly invests in equity and mutual funds with its primary focus on pharmaceuticals, banking, and energy sectors.
  • The company has leased out its two factories from 1st, November 2017 and thus the company is dependent on lease rental from only one party. 
  • The company's shares has been listed at Metropolitan stock exchange.
  • Sigachi Laboratories Limited is a public company incorporated on 21st November 1994. It is classified as a non-government company and is registered at Registrar of Companies, Hyderabad.
  • The company's management includes Lekha Sai Surapaneni, Lakshmana Venkata Subba Rao Patchipulusu, Tadepalli Rao Govardhana, T Adinarayana, G M Rao, K Suneetha, TR Sekhar.

  • Sigachi Laboratories IPO Details

Currently, the company has no plans to raise funds through IPO.

  • Sigachi Laboratories Subsidiaries

The company does not have any subsidiaries/ joint ventures/ associates.

  • Sigachi Laboratories Revenue Segmentation

  • Revenue from Operations
  • Bulk drugs and Intermediate - Lease rents
  • Interest Income
  • Other Income

  • Sigachi Laboratories Product & Services

  • Bulk drugs
  • Intermediate drugs

  • Sigachi Laboratories Assets

Assets of the company as on 31st, March 2021.

Particulars Amount in Rs. Lakhs
Freehold Land75
Buildings62
Plant and Equipments88
Vehicle35
Office Equipments0.39

  • Sigachi Laboratories Industry Overview

Industry Statistics

Pharmaceutical Industry-  
  • The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate symptoms. Pharmaceutical companies may deal in generic or brand medications and medical devices
  • In FY21, India's pharmaceutical market was valued at Rs 2,150.9 bn (USD 29.0 bn), experiencing a 11.4% increase from FY20.
  • Due to a large consumer base, increased healthcare expenditure, disease prevalence, and the presence of supportive regulatory regimes, emerging pharmaceutical markets are likely to grow rapidly in the coming years. In addition, the region is rapidly adopting new technology and undergoing digital transformation.
  • India is expected to attract multinational drugmaker investment, underpinning its long-term growth potential. The outlook for medicine sales in the country remains positive and will be boosted by a confluence of several important drivers, such as increasing healthcare quality, a large and growing population and the expansion of the universal healthcare scheme. Generic drugmakers will be the greatest beneficiaries from this expected medicine sales growth in the coming years, given the low affordability levels.
  • The Indian pharmaceutical industry is the world’s 3rd largest by volume and 14th largest in terms of value. Total annual turnover of pharmaceuticals was Rs. 2,89,998 Cr. for the year 2019-2020. Major segments of pharmaceutical industry are generic drugs, OTC medicines and API/Bulk drugs, vaccines, contract research & manufacturing, bio-similars & biologics.
  • India enjoys an important position in the global pharmaceuticals sector. India also has a large pool of scientists and engineers with the potential to steer the industry ahead to greater heights. 

Investments - 

  • The company, in FY21, mostly derived its revenue from equity instruments and mutual funds. The sectors in which the investments were carried out are banking, pharmaceuticals, and the energy sector. 
  • Assets Under Management (AUM) of Indian Mutual Fund Industry as on January 31, 2022 stood at ₹38,01,210 crore.
  • The AUM of the Indian MF Industry has grown from ₹ 6.59 trillion as on January 31, 2012 to ₹38.01 trillion as on January 31, 2022 more than 5½ fold increase in a span of 10 years.
  • The MF Industry’s AUM has grown from ₹ 17.37 trillion as on January 31, 2017 to ₹38.01 trillion as on January 31, 2022, more than 2 fold increase in a span of 5 years.
  • Value-oriented mutual fund schemes or value funds offered an average return of 35% in 2021, according to Value Research. These schemes have given around the same 35% returns this year till date. The benchmark S&P BSE 100 TRI offered around 25.99% in FY21.
  • The NIFTY private bank index is designed to reflect the performance of the banks in the private sector, which generated a total return of 14% in 1 year as of January 31, 2021.
  • NIFTY Pharma Index captures the performance of the pharmaceutical sector. The Index comprises of 20 companies listed on national stock exchange of India (NSE), which generated a total return of 9% in 1 year as of 31st, January 2021.
  • The Nifty Oil & Gas Index is designed to reflect the behaviour and performance of the companies belonging to Oil, Gas and Petroleum industry which generated a total returns of 48.38% in 1 year as of 31st, January 2021. 

Future Prospects

Pharmaceutical - 

  • Over the forecast period to 2025, pharmaceutical market is expected to reach a value of Rs. 3,781.4 bn (USD 45.0 bn), experiencing a compound annual growth rate (CAGR) of 11.9% in local currency terms (9.2% in US dollar terms). Over the extended forecast period, medicine sales is expected to experience a 10-year CAGR of 11.3% and 9.7% in local currency and US dollar terms respectively, reaching Rs. 6,290.2 bn (USD 73.06 bn) by 2030. In 2020, per capita pharmaceutical sales remained low at USD 21.03, which places high-value pharmaceutical products out of reach for the majority of patients. Pharmaceutical sales as a percentage of GDP was 1.12% in 2020 and is expected to increase over 10-year forecast period. 
  • According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade. India's domestic pharmaceutical market is estimated at US$ 42 billion in 2021 and likely to reach US$ 65 billion by 2024 and further expand to reach ~ US$ 120-130 billion by 2030.
  • India’s medical devices market stood at US$ 10.36 billion in FY20. The market is expected to increase at a CAGR of 37% from 2020 to 2025 to reach US$ 50 billion.
  • As of August 2021, CARE Ratings expect India's pharmaceutical business to develop at an annual rate of ~11% over the next two years to reach more than US$ 60 billion in value.

Government Initiatives

Pharmaceutical - 
  • 'Pharma Vision 2020’ by the Government’s Department of Pharmaceuticals aims to make India a major hub for end-to-end drug discovery. The Indian drugs and pharmaceuticals sector received cumulative FDIs worth US$ 18.12 billion between April 2000 and June 2021. The foreign direct investment (FDI) inflows in the Indian drugs and pharmaceuticals sector reached US$130 million between April 2021 and June 2021.
  • Under Union Budget 2021-22, the Ministry of Health and Family Welfare has been allocated Rs. 73,932 crore (US$ 10.35 billion) and the Department of Health Research has been allocated Rs. 2,663 crore (US$ 365.68 billion). The government allocated Rs. 37,130 crore (US$ 5.10 billion) to the 'National Health Mission’. PM Aatmanirbhar Swasth Bharat Yojana was allocated Rs. 64,180 crore (US$ 8.80 billion) over six years. The Ministry of AYUSH was allocated Rs. 2,970 crore (US$ 407.84 million), up from Rs. 2,122 crore (US$ 291.39 million).
  • The government had also proposed that formulations produced with indigenous APIs be given preference in government procurement.
  • Department of Chemicals and Petrochemicals (DPCO) governs prices of all bulk drugs and formulations to ensure widespread availability of medicines at reasonable prices. Together, the Indian Patent Act and the DPCO significantly influence the structure and growth pattern of the domestic pharmaceutical industry. 

Sigachi Laboratories Strengths

  • The company is completely debt-free as the company must fund its project through fair value gains and equity of the company.
  • The company generated most of its revenue in FY21 from investments. The company has a very diversified portfolio, which will help the company to realise capital gains as well as support a business of bulk and intermediate drugs if the market changes unexpectedly, which is expected to grow at 9-11% in FY22. 

Sigachi Laboratories Shortcomings

  • The majority of the revenue of the company has not been realised from its main business, i.e., bulk drugs and intermediate drugs manufacturing, despite the growth in the pharmaceutical industry.
  • The company doesn't reap the benefits of using financial leverage, which could help them realise higher returns. 
  • The company is subject to market fluctuations and that gives them exposure to downside risk if the market doesn't perform as expected.
  • The company has not made any expenditures on research and technology, which are very crucial in the pharmaceutical industry. 

Sigachi Laboratories Opportunities

  • The global recovery is speeding up. Uptum is likely to be aided by continuing infrastructure investments, supply-side reforms, low-interest loan disbursement, and regulatory ease.
  • The government and the Reserve Bank of India took a number of policy actions to assist set the pace, including a stimulus package, dramatic policy rate cuts, a lending moratorium, and measures to improve liquidity, among other things.
  • Economic growth, rising chronic illness incidence, increased healthcare access, and predicted per capita income growth will fuel further expansion of the healthcare sector, as well as the development of vaccines and other formulations for the Covid 19 virus. As a result, Pharma Businesses have the potential to expand.

Sigachi Laboratories Threats

  • The emerging pharmaceutical industry may face the threats like (i) reduced demand for prescription medicine; (ii) growing competition from generic pharmaceuticals; (iii) rising consumer expectations and difficulties managing brand health; (iv) data breaches and other cyber security threats; (v) supply chain disruptions.
  • Many pharmaceutical businesses' sales and margins may suffer as a result of drug price controls.
  • The pharmaceutical sector is fiercely competitive, with Indian manufacturers with similar production facilities as well as those from other countries posing threats. Human resources in the business with equivalent skills, talent, and experience are mobile across competitors.
  • Unfavorable changes in rules and regulations could have a negative influence on all businesses in the market.
Sigachi Laboratories Rating

  • RECOMMENDATION

    Sell

  • Sigachi Laboratories Detail Info

Industry Statistics

PRIVATE LIMITED

Registered In

India

last Updated

14/02/2022

Registered Date

21/11/1994

Planify Ticker

SLAB

Reg Office: SIGACHI LABORATORIES LIMITED SR.NO.530 & 534 JINNARAM MANDAL MEDAK DISTRICT BONTHAPALLY ANDHRA PRADESH INDIA-502313

Frequently Ask Questions

Sigachi Laboratories Limited has expressed no intention of raising funds through IPO.

The face value of Sigachi Laboratories Limited share is Rs. 10

Yes, Sigachi Laboratories Limited is expected to make good profits in the future.

Sri. T. Adinarayana is the chairman of Sigachi Laboratories Limited.

Sri. T. Adinarayana is the owner of Sigachi Laboratories Limited. He holds 11.16% stake in the company.

Sigachi Laboratories Limited is completely debt-free as the company must fund its project through fair value gains and equity of the company.

We recommend a "Sell" rating on Sigachi Laboratories Limited Shares.

The total profit of Sigachi Laboratories Limited is Rs. 2.75 Cr. in FY21.

Please find below the procedure for buying stock_name_auto Unlisted Shares at Planify.
• 1. You confirm booking of stock_name_auto Unlisted Shares with us at a trading price.
• 2. You provide your client master report (ask the broker if not available) along with PAN Card and Cancelled Cheque in case you are not transferring funds from the bank account as mentioned in the CMR Copy. These are KYC documents required as per SEBI regulations.
• 3. We will provide the bank details.
• 4. You need to transfer funds in that account.
• 5. Payment has to be done in RTGS/NEFT/IMPS CHEQUE TRANSFER. No CASH DEPOSIT.
• 6. Payment has to be done from the same account in which shares are to be credited.
• 7. We will transfer the shares in 24 hours if funds are credited before 2 pm.
Important Note: Please note that the lock-in period for selling stock_name_auto Unlisted Shares is 6 months after listing. Hence you can’t sell stock_name_auto Unlisted Shares which you bought in Pre-IPO for 6 months after its listing. i.e. You can sell it only after 6 months calculated from the listing date.

Please find below the procedure for selling stock_name_auto Unlisted Shares at Planify.
• 1. We will confirm our buying price of stock_name_auto Unlisted Shares.
• 2. We will give you our client master report and you will transfer the stock_name_auto Unlisted Shares to our demat account.
• 3. We will ask for bank details of yours once the stock_name_auto Unlisted Shares are received in our demat account..
• 4. We will transfer the funds in your bank account within 24 hrs of receiving the stock_name_auto Unlisted Shares.
• 5. Payment will be made in RTGS / NEFT / CHEQUE TRANSFER/IMPS. No CASH DEPOSIT.
• 6. Payment will be given in the same account which is linked to demat account or you need to provide the cancelled cheque shows your name to verify. As per SEBI regulations, the transfer of funds in the third party account is not legal and our policy refrain us from doing so.
Note: The price at which we are buying the share is fixed for 3 days. If you cant sell your stock within 3 days, then the price of that day will be applicable when we receive shares in our demat.

Lock-in period of stock_name_auto Unlisted Shares depends upon category of investors.
• 1. Venture Capital Funds or Alternate Investment Fund of Category -I or II, or Foreign Venture Capital Investor - lock-in Period of 6 months from the date of acquisition of stock_name_auto Unlisted Shares.
• 2. Other Investors (include Retail, HNIs or Body Corporate) lock-in Period of 6 months from the date of listing of IPO of stock_name_auto Unlisted Shares.
This new SEBI rule was introduced in the month of August-2021, wherein the SEBI has reduced the lock-in period previously from 1 year to 6 months to encourage more and more funds to be invested in startups which are going to public or IPO in near future. Reduction of lock-in is seen as big step and after that many PMS funds are advising their clients to invest in Pre-IPO shares to get the benefit of early stage investment.

DIS - Delivery Instruction Slip is the way through which an investor can sell or transfer the stock_name_auto Unlisted Shares from his/her demat account to any other demat account. There are two Types of DIS Slip.
1. Offline-DIS - This is an offline mode of transfer of shares wherein the investors needs to fill DIS form and give it to their broker for transferring the shares. Following are the fields which are required to be filled.
• a. ISIN number of stock_name_auto Unlisted Shares.
• b. Name of stock_name_auto Unlisted Shares
• c. Quantity of stock_name_auto Unlisted Shares
• d. Cosideration Amount
• e. Target DP ID and Client ID
• f. Annexure
2. Online DIS - Some of the broker these days gives facility of transferring the stock_name_auto Unlisted Shares via online DIS. So, please check with your broker whether such facility is available or not. For example: Angel Broking proivdes the facility of Online-DIS from its platform. As an investor he/she simply needs to add a beneficiary into it and send the stock_name_auto Unlisted Shares by filling the details similar to Ofline-DIS.

In the last 4-5 years, the unlisted share market has become quite big and as a result of that, the ticket size has reduced from usual 5-10 Lac to 35-50k in today's scenario. So, via our Planify platform, if somebody wants to buy stock_name_auto Unlisted Shares then minimum investment would be 35-50k.

Yes, buying and selling of unlisted shares in India is 100% legal.

If you sell your shares within 2 years, then you will have to pay Short-term Capital gain on unlisted shares. Short-Term Capital Gain is added in your Income. So, as per individual tax slab you need to pay capital gain tax.

If you sell your shares after 2 years, then you will have to pay Long-term Capital gain on unlisted shares LTCG is 20% with indexation benefits.

Taxes will remain the same irrespective of listing of shares, if bought in unlisted market. Actually, to be eligible for taxes as per listed market, one has to pay STT on buying and selling of shares. But, if you buy in unlisted and sell in listed market, one pay STT only on selling so, taxes of listed market will not be applicable.

If you buy stock_name_auto Unlisted Shares from Planify then these shares can checked in two ways. However, before we tell you the process of checking of shares, it is intimated that as per SEBI regulations, the shares can be transferred in demat account only.
Check credit of stock_name_auto Unlisted Shares Instantly?
• 1.You can download the NSDL or CDSL application from google play-store and check. If you want to check whether your stock broker is registered with NSDL or CDSL then check the following procedure.
• By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Demat Account = DP ID + Client ID. (16 Characters )
• "DP ID is the unique identification of the Broker. Every broker gets a unique number from CDSL or NSDL.By carefully examining the number format of Demat Account we can easily identify whether the stock broker is registered with CDSL or NSDL.
• Client ID is the unique identification of the Client. Every client gets this unique number which represents his/her portfolio.
• In CDSL, all these characters are numbers (1234567891234567) first 8 digits are DP ID and next 8 digits are Client Id whereas in NSDL the first two characters are letters which are in accordance with the country that you are from (IN12345678912345), then 6 unique digits for Broker and next 8 digits are client ID.
• Example:
• CDSL = 12345678(DP ID) and 91234567(Client ID).
• NSDL = IN123456 (DP ID) and 78912345(Client ID).
• Check in brokers application?
• Credit of stock_name_auto Unlisted Shares can be checked in brokers application as well but it takes T+2 days to show the shares.

The stock_name_auto Unlisted Shares are credited in demat account same day of transferring funds in our company's bank account.

The price of stock_name_auto Unlisted Shares can be checked in two ways. First, you can join our telegram channel where on daily basis we share the latest prices of all the unlisted shares in the morning and secondly, you can register on Planify.live platform to see the historical graphs and prices of all the shares at one place.

If you see the thesis of investment in the unlisted shares then it is being done mainly to take the advantage of IPO market. And, if the IPO plans of company get delayed due to market conditions or any other reason then demand suddenly drops in the market. The unlisted market works mainly on demand and supply and if there is no IPO news then getting exit would be difficult.

"Planify is India's fastest and leading marketplace to buy and sell unlisted shares. In the last 3 years, we have already served more than 1 million users on the platform. The total transactions value done from the platform is already more than 100 Crores. The name of our Co-founders Mr. Umesh Paliwal and Dinesh Gupta publish regularly in leading newspapers like MoneyControl, Business-Standard, ET etc for their views on IPO and Unlisted market. In the last 3 years, Planify has made a good name for itself in the industry and gained a trust of their users. So, the new investors should not be worried about any kind of fraud that is mostly happens with unkown brokers in the market while doing investment with Planify."

We at Planify do the valuation based on 2 methods.
• 1. We check the last funding that is being done in the stock_name_auto Unlisted Shares to ascertain the benchmark valuation.
• 2. If there is no funding happened in the company, then we try to find a business similar to stock_name_auto Unlisted Shares in the listed space and do comparison method to ascertain the valuation.
As an investor in the unlisted space, we would always recommend that you must check all the risk parameter carefully before investing in the unlisted space.

We source shares either from the employees or initial investors looking to liquidate their stock_name_auto Unlisted Shares.

Pre-IPO shares means which are planning for an IPO in near future. So, all the shares which are traded on the platform are not Pre-IPO Shares. However, if the company's business is going good and then demand will always be there in the unlisted space, so even if the IPO does not come, the investors can easily liquidate their stock_name_auto Unlisted Shares in the unlisted market itself.

Rules and regulations of SEBI are applicable in the Unlisted space like lock-in period of 6 months, paying of Stamp Duty, and DP Charges for every transaction etc. However, to become an unlisted broker there is no such regulation by SEBI as of yet.

For tracking news and other information about stock_name_auto Unlisted Shares, one can visit our website wherein we post news and other information on daily basis and one can also join our telegram channel.

Fundamental & Comparative valuation models and the forces of demand and supply in the market for unlisted shares dictate the price. These prices are based on our estimates and transaction history of stock_name_auto Ltd unlisted share.

We can generally arrange lot sizes starting with an investment of INR 20,000. To confirm the lot sizes of stock_name_auto Ltd unlisted shares with us.

The financials of stock_name_auto Ltd which includes the P/L of stock_name_auto Ltd and the Balance Sheet of stock_name_auto Ltd is in the financials section.

The annual report of stock_name_auto Ltd is available in the annual report section.

  • Sigachi Laboratories Share Price

  • ₹58.00

  • PLACE ORDER
  • ROFR Required

Available in Depository

  • NSDL

  • CDSL

Available for Investment

  • Primary

  • Secondary

  • Investment Checklist

Management

Accounting Practice

Profitability

Solvency

Growth

Valuation